Key result
Direct oral anticoagulants demonstrated superior safety and efficacy compared to warfarin, reducing rates of all-cause death, ischemic stroke, severe bleeding, and cerebral hemorrhage.
Why the study?
Do direct oral anticoagulants improve safety and efficacy compared to warfarin in atrial fibrillation patients with chronic liver disease?
Meta-Analysis
Do direct oral anticoagulants improve safety and efficacy compared to warfarin in atrial fibrillation patients with chronic liver disease?
p-value: p=.004
In patients with atrial fibrillation and chronic liver disease, DOACs appear to offer superior efficacy and safety profiles compared to warfarin, particularly in reducing bleeding and stroke risks.
Supports preferring DOACs over warfarin in AF with chronic liver disease; extends general-population evidence to this subgroup.
= .004). Secondary outcomes revealed a significantly reduced risk of major bleeding with DOACs compared to warfarin, while gastrointestinal bleeding showed a non-significant decrease. Intracranial hemorrhage risk was significantly lower with DOACs compared to warfarin. DOACs demonstrate superior safety and efficacy compared to warfarin, evidenced by reduced rates of all-cause death, ischemic stroke, severe bleeding, and cerebral hemorrhage. Further randomized controlled trials are essential to enhance the evidence base for DOACs across diverse patient populations.
No takes yet. Share an insight, caveat, or question.
Jaffari et al. (2024) conducted a meta-analysis in Atrial Fibrillation with Chronic Liver Disease. Direct Oral Anticoagulants (DOACs) vs. Warfarin was evaluated (p=.004). Direct oral anticoagulants demonstrated superior safety and efficacy compared to warfarin, reducing rates of all-cause death, ischemic stroke, severe bleeding, and cerebral hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: